Overreaching. Over promising. Under delivering.
"Indication of efficacy designed to be available within 18 months" (Sept 2016)
- WE EXPECT TO KNOW WITHIN 12 MONTHS OF THE SUCCESS OF OUR MISSION (Nov 2016)
- AIM: • to have proof-of-concept by end-2017 • decision on indication for registration studies by end of 1Q-2018> https://www.noxopharm.com/site/PDF/1117_0/CorporatePresentationUpdated
Overreaching. Over promising. Under delivering. "Indication of...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 52445 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 14000 | 1 |
View Market Depth
| Last trade - 09.52am 27/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable
